argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-04 07:54 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 22.7 KB | ||
| 2023-05-02 07:51 |
argenx to Present at BofA Securities 2023 Health Care Conference
|
English | 17.6 KB | ||
| 2023-04-27 08:47 |
argenx to Report First Quarter 2023 Financial Results and Business Update on Ma…
|
English | 21.2 KB | ||
| 2023-04-18 07:53 |
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized My…
|
English | 76.7 KB | ||
| 2023-04-17 08:23 |
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology…
|
English | 45.3 KB | ||
| 2023-03-20 07:44 |
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
|
English | 23.5 KB | ||
| 2023-03-16 21:00 | English | 17.3 MB | |||
| 2023-03-15 16:51 |
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized M…
|
English | 52.6 KB | ||
| 2023-03-02 07:47 |
argenx Announces Planned Transition of Chief Operating Officer
|
English | 41.0 KB | ||
| 2023-03-02 07:46 |
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Bus…
|
English | 163.2 KB | ||
| 2023-02-28 08:06 |
argenx Appoints Steve Krognes to Board of Directors
|
English | 135.0 KB | ||
| 2023-02-27 10:44 |
argenx to Present at Upcoming Investor Conferences
|
English | 20.7 KB | ||
| 2023-02-23 08:53 |
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business U…
|
English | 19.4 KB | ||
| 2023-01-27 07:37 |
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
|
English | 30.7 KB | ||
| 2023-01-17 07:37 |
argenx Announces Extraordinary General Meeting of Shareholders on February 27, …
|
English | 24.1 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
